leadforensics

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies. Find out more about cookies.

Click here to dismiss this banner

PHARMA REPORT

rss_Pharma.jpg...see all
Stem Cells - The Hype & Hope - World Analysis 2009-2024

Stem Cells - The Hype & Hope - World Analysis 2009-2024

  • Publication date: 23/03/2009
  • Number of Pages: 155
  1. Report Details
  2. Table of Contents
  3. Companies Listed

Report Details

Stem cell technologies – changes to US regulations to give exciting new hopes and potentially vast commercial opportunities – brand new indepth study

Stem cells represent one of the most promising medical breakthroughs of all time, as our new market report explains. Currently, in 2009, the new US administration is lifting some major restrictions on stem cells technologies. This developmental obstacle now removed, all types of stem cells are available for expanding the therapeutic and commercial potentials, as our new report Stem Cells – The Hype & Hope – World Analysis 2009-2024 explains. Based upon the cells that create and renew all tissues potentially, stem cell therapies could revolutionise the treatment of disease, especially through tissue and organ replacement. Stem cells could provide revolutionary treatments for conditions from diabetes to multiple sclerosis, and from myocardial infarction to chronic obstructive pulmonary disease, amongst many others. Stem cell lines could also change the way pharmaceutical companies assess new chemical entities during R&D.

A conservative estimate places the potential market value of stem cells at over $150bn by late next decade. But will stem cell products be ready to meet regulatory hurdles and market requirements? Where is stem cell research heading today? What stem cell therapies are likely to hit the market from 2009 onwards? Where does the highest value lie in the short-term? What are the commercial threats there? This new Visiongain report answers these and other crucial questions about this important developing field, one with vast commercial potential.

Comprehensive analysis of the global stem cells sector and market
Stem Cells – The Hype & Hope – World Analysis 2009-2024 examines stem cells technology critically. We used a comprehensive review of information sources, including consultations with relevant experts. This report provides detailed sales forecasts, discussions of pipeline developments and analyses of important contemporary issues, especially relevant commercial drivers and restraints. This report also covers regulations and ethics. Sources used include commercial databases, industry news, published reports, policy documents and economic research. Importantly, Visiongain applied rigorous financial forecasting, qualitative analyses and the assessment of unmet needs. The result is a comprehensive market- and industry-centred report with detailed analysis and informed opinion that you will not find elsewhere.

Why you should buy this report:
Key information that you will find in Stem Cells – The Hype & Hope – World Analysis 2009-2024 includes:
• Analyses of the existing market value for stem cells
• Analyses of the potential market value of stem cell therapies, including detailed revenue forecasts from 2009 to 2024
• Forecasts for existing stem cell markets, including private cord blood banks and Osiris Therapeutics and NuVasive’s Osteocel
• Discussions of ethical complications and situations that influence the way stem cell medicine is perceived, researched and conducted
• Analyses of key organisations, suppliers and relevant national laws
• Expert opinions from original research interviews with key opinion leaders in stem cells research and technology
• Informed analyses of the strengths and weaknesses of the technologies from 2009 onwards
• Balanced assessments of commercial drivers and restraints in the stem cells field.
• Visiongain believes that stem cell technologies are progressing rapidly. We predict that more products will enter the market over the coming 5 years, changing the commercial landscape for stem cells. 

You can order this report today
Nobody with an interest in the stem cells field can afford to overlook this new market study from Visiongain. The market environment in many countries will change, especially after favourable developments in the US in early 2009. Visiongain predicts that revenues for stem cell technologies will increase greatly from 2009 to 2024, with important events shaping trends. Will stem cells revolutionise medicine in the foreseeable future? What are the main obstacles to overcome there? What revenues can be achieved? This report covers those vital questions and many more. Do you want to know more about this important market? You can stay ahead in this exciting field by ordering this report today.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Table of Contents

1 Executive Summary
1.1 The Focus of This Report: "Stem Cells Therapy" versus "Regenerative Medicine"
1.2 Crucial Aspects of the Stem Cell Market
1.2.1 Summary Points
1.2.2 Potential Sales Values
1.3 Aims, Scope and Format of This Report
1.3.1 The Speculative Aspects of Assessing the Stem Cell Field
1.3.2 Chapter Outline
1.4 Research Methods

2 Stem Cells: Types and Sources
2.1 Defining Characteristics
2.1.1 Multipotency vs. Pluripotency
2.1.2 Germ Layers and Multipotent Cells
2.2 Embryonic Stem Cells
2.2.1 Abortion Debates, IVF, and Embryonic Stem Cells
2.2.2 Harvesting Human Eggs
2.3 Cybrids: Controversial Animal-Human Hybrids
2.3.1 "Disease in a Dish" Models Using Cybrids
2.3.2 Cybrids and Therapeutic Cloning
2.3.3 Animal or Human?
2.4 Adult Stem Cells
2.4.1 Tissue / Body Part Sources of Adult Stem Cells
2.5 Cord Blood: The "Natural" Source of Embryonic Stem Cells
2.5.1 "Cord-Blood-Derived Embryonic-Like Stem Cells" (CBE)
2.5.2 CBEs: Ethical and Available
2.5.3 Cord Blood Proven to Cure
2.5.4 The Odds of Needing a Blood Stem Cell Transplant
2.5.5 Cord Blood: Private Hope or Public Salvation?
2.5.5.1 Tissue Matching Can be Less Precise with Cord Blood
2.5.5.2 Extra-Familial Tissue Matching
2.5.5.3 Private Cord Blood Banking: Biological Insurance
2.5.5.3.1 Regional Rules on Private Cord Blood Banking
2.5.5.3.2 US Oversight of Cord Blood Stem Cells
2.6 Commercial Potential of Cord Blood Banks: Market Forecast
2.6.1 86% of Banks Established post-2000
2.6.2 Banks' Added Value
2.7 Do Stem Cells Cause Cancer?
2.7.1 Cancer Metastasisation Caused by Rogue Stem Cells?
2.7.2 Potency Re-programming Requires Insertion of Cancerous Gene
2.7.3 Will Stem Cell Treatments Cause Cancer?

3 Established Stem Cell Treatments
3.1 Bone Marrow Transplants: 40+ Years of Success
3.2 Peripheral Blood Stem Cells: Gaining Ground
3.3 Cord Blood Stem Cells
3.4 Graft-Versus-Tumour Effect: Donated Cells Kill Host's Cancer Cells
3.4.1 Allogenic Transplants are Better for Killing Cancer
3.5 Graft-Versus-Host Disease: When Host and Transplant Do Not Mesh
3.5.1 Prochymal: Treatment for GvHD
3.6 Host-Versus-Graft: When Stem Cells are Rejected
3.7 "Saviour-Siblings": Stem Cells from a Sibling, Created or Chosen to be a Saviour
3.7.1 UK Cases and Rules on Saviour Siblings
3.7.2 Regardless of the Ethics, Saviour Sibling Stem Cells Work

4 Emerging Stem Cell Treatments
4.1 Prochymal - Poised to be the First Revolutionary Stem Cell Treatment
4.1.1 Market Value of Prochymal Indications
4.1.2 Crohn's Disease
4.1.3 Chronic Obstructive Pulmonary Disease
4.1.4 Diabetes and Prochymal
4.1.5 Cardiac Indications
4.1.6 Graft-Versus-Host Disease
4.1.7 Prochymal and Acute Radiation Syndrome
4.1.7.1 Proof-of-Concept for Prochymal for ARS
4.2 Osteocel Market Forecast: Osiris's First Marketed Product, Now Sold by NuVasive
4.2.1 Osteocel: The Only Marketed Product with Viable Stem Cells
4.2.2 Osteocel XC
4.3 Other Wound Healing / Surgical Healing
4.4 Heart and Artery Repair
4.5 Autoimmune Diseases
4.5.1 Crohn's Disease
4.5.2 Diabetes Types 1 and 2
4.5.3 Multiple Sclerosis
4.6 Reducing Rejection: Addressing Graft-Versus-Host Disease
4.7 Paralysis Treatments: Geron's GRNOPC1. (The First Embryonic Stem Cell Clinical Trial)
4.7.1 How Much GRNOPC1 Can Geron Make?
4.8 Therapeutic Cloning / Somatic Cell Nuclear Transfer
4.8.1 Organ Transplants: Can Therapeutic Cloning Make Them Obsolete?
4.8.2 Growing Organs
4.8.3 Somatic Cell Nuclear Transfer for Disease Models

5 Leading Stem Cell Therapy Companies
5.1 Osiris: First to Market with Stem Cells
5.1.1 Prochymal and 2008
5.1.2 Osiris and NuVasive
5.1.3 Osteocel Sales Forecast
5.1.4 Osiris and Genzyme Marketing Agreement
5.1.5 Osiris and Boston Scientific: Partnership Ended 2008
5.2 Genzyme
5.3 Geron: First Embryonic Stem Cell Trial
5.4 Novocell: Looking to Follow Geron in Embryonic Stem Cell Trials
5.4.1 Johnson & Johnson and Novocell
5.4.2 Pfizer and Novocell
5.5 Pfizer and Induced Pluripotent Stem Cells (iPS)
5.6 Novartis: The Genomics Institute of the Novartis Research Foundation (GNF)
5.7 MediStem, Inc. (MediStem Laboratories, Inc.)
5.8 Regenetech
5.8.1 Biogenea-CellGenea
5.9 Neuralstem, Inc.
5.10 Advanced Cell Technology (ACT)
5.10.1 ACT and Transition Holdings, Inc.
5.10.2 ACT and CHA Biotech Co., Ltd.
5.10.3 ACT Acquired Mytogen, Inc.
5.11 Garnet BioTherapeutics / Neuronyx
5.12 Pluristem Therapeutics, Inc.
5.13 BrainStorm Cell Therapeutics
5.14 Cellerix: Ontari has EMA Orphan Drug Status
5.15 ReNeuron
5.16 CellCure Neurosciences, Ltd.
5.17 Athersys
5.18 Royan Institute (Tehran)
5.19 Reliance Life Sciences, India
5.20 Cytori Therapeutics

6 Major Stem Cell Suppliers
6.1 StemCell Technologies
6.1.1 Geron and StemCell Technologies
6.2 ES Cell International, Singapore: Aiming for the First Marketed Product Including Embryonic Stem Cells
6.3 Stemride International Limited (SIL) and Reproductive Genetics Institute, Chicago: Normal and Abnormal Cell Lines
6.4 Merck / Calibochem
6.4.1 Stem Cell Sciences and Merck
6.5 Cellular Dynamics International (CDI)
6.5.1 Roche and Cellular Dynamics: Pioneering Toxicity Assays
6.6 HyClone / Thermo Fisher Scientific
6.7 Stemgent
6.8 Stem Cell Innovations (SCI)
6.9 Axiogenesis (Germany)
6.9.1 Roche and Axiogenesis
6.10 StemLifeLine: Embryonic Stem Cells Without Embryo Destruction?

7 Overview of Regional Embryonic Stem Cell Regulations and Funding Bodies
7.1 Pan-Europe: Roche, GlaxoSmithKline and AstraZeneca
7.2 United States
7.2.1 California Stem Cell Research and Cures Initiative (Proposition 71) and The California Institute for Regenerative Medicines
7.2.1.1 Stanford University Received $75 Million for Stem Cell Research
7.2.1.2 UC Irvine Received $27 Million for Stem Cell Research Center
7.3 United Kingdom
7.3.1 The London Regenerative Medicine Network (LRMN)
7.4 Sweden
7.5 Switzerland
7.6 Belgium
7.7 France: Reassessing Embryonic Research in 2009
7.8 Less-Permissive European Countries for Stem Cells
7.8.1 Germany
7.8.2 Norway
7.8.3 Italy
7.9 Canada
7.10 Russia
7.11 Israel: At the Forefront of Research; Reproductive Cloning Ban Up for Reassessment in 2009
7.12 Gulf Countries: Funding Biotechnology, Funding Stem Cell Research
7.13 Singapore: Advanced and Prominent in Stem Cells
7.14 China: Open to the Potential of Stem Cell Technologies
7.15 India: First Stem Cells Facility Due to Open in 2009
7.16 Australia and the Australian Stem Cell Centre
7.17 Japan
7.18 South Korea
7.19 South Africa

8 Visiongain Interviews with Stem Cell Experts
8.1 Dr. Johan Luthman, PhD., Global Head of Exploratory Medicine (Neurology, Autoimmune & Inflammatory Diseases), Merck Serono (a division of Merck KGaA)
8.1.1 On the Difficulties of Translational Medicine
8.1.2 On the Differences Between Technology and Media Perceptions
8.1.3 On Confusion in the Media
8.1.4 On Stem Cells and Neurologic Disorders
8.1.4.1 On Which Neurological Disorders will be Treated First
8.1.4.2 On Multiple Sclerosis
8.1.5 On Why Stem Cell Results Take a Long Time
8.1.6 On When Stem Cell Therapies Will Reach the Market
8.1.7 On the Distinction between Regenerative Medicine and Stem Cell Therapies
8.2 Dr Stephen Minger, Senior Lecturer and Director of King's College London's Stem Cell Biology Laboratory (Wolfson Centre for Age-Related Diseases)
8.2.1 On Whether Adult or Embryonic Stem Cells Should Receive More Funding/Support
8.2.2 On Cord Blood and Embryonic Stem Cells
8.2.3 On the Need for More Immunological Assays
8.2.4 On How Long Until There are Human Stem Cell Therapies
8.2.5 On Cord Blood as a Source of Stem Cells
8.2.6 On Private Cord Blood Banking
8.2.7 On Therapeutic Cloning
8.2.7.1 On Therapeutic Cloning and Tissue Type Cell Lines
8.2.8 On the Promising and Unusual Immunological Properties of Embryonic Stem Cells
8.2.9 On Mesenchymal Stem Cells and Inflammation
8.2.10 On the Suggestive Use of Foreskin Fibroblasts
8.3 Gregory Bonfiglio, Proteus Venture Partners
8.3.1 On the Terms "Stem Cell Therapy" and "Regenerative Medicine"
8.3.2 On "Near Term" Applications
8.3.3 On the Value-Creation Curve for Venture Capital in Stem Cells
8.3.4 On There Being No Known Limits for Stem Cell Possibilities
8.3.5 On Stem Cells in 25 Years
8.3.6 On Funding as a Primary Limitation
8.3.7 On Stem Cells in Multiple Sclerosis and Diabetes Type 1
8.3.8 On Cord Blood
8.3.9 On Extracellular Matrixes
8.3.10 On Disease-Specific Cell Lines
8.3.11 On Adult vs. Embryonic Stem Cells
8.3.12 On Where There is Capital for Stem Cell and Regenerative Medicine Research
8.4 Josephine Quintavalle, Founder of Comment on Reproductive Ethics (CORE)
8.4.1 On Embryonic Stem Cells and Dehumanisation
8.4.2 On HFEA Regulation for Embryo Destruction
8.4.3 On Economics and Scientific Effectiveness
8.4.4 On Cord Blood
8.4.5 On Adult Stem Cell Therapies and the Economics of Therapy
8.4.6 On Public, Private and Private/Public Cord Blood Banks
8.4.7 On International Studies and International Communication

9 Market Value Potentials and Projections
9.1 Visiongain's Stem Cells Market Projection
9.1.1 Complexities of Analysis
9.1.2 Bases for Visiongain's Market Projection
9.2 Forecast by Market Subdivision
9.2.1 Laboratory Supplies
9.2.2 Bone Marrow Transplants
9.2.3 Organs and Tissues

10 SWOT Analysis
10.1 Strengths and Weaknesses
10.1.1 Strength in Numbers
10.1.2 Weakness in Fragmentation
10.1.3 Weakness in Funding Uncertainties
10.2 Opportunities and Threats
10.2.1 Opportunities Abound
10.2.2 The Constant Threat of Politics

11 Conclusions
11.1 The Hope
11.2 The Hype
11.3 The Short-Term Future
11.4 The Long-Term Future

Appendix: Religious Perspectives on (Embryonic) Stem Cells
1 Catholicism
2 Protestantism
3 Judaism
4 Islam
5 Hinduism

List of Tables
Table 2.1 Types of Cellular Potency and Sources of Cells
Table 2.2 Germ Layers and Associated Cells/Organs
Table 2.3 Adult Stem Cell Sources
Table 2.4 Private / Family Cord Blood Banks Sales Forecast, 2009-2024
Table 4.1 Market Value of Selected Prochymal Future Indications, Based Upon Sales Through Q3 2008
Table 4.2 Osteocel Sales Forecast, 2009-2024 (including Osteocel XC)
Table 4.3 Clinical Trials of Stem Cell Studies for Surgical or Injury Healing, Phases I-III, 2009
Table 4.4 Stem Cell Heart Repair Clinical Trials, Phases III-IV, 2009
Table 4.5 Clinical Trials for Autoimmune Diseases (non-Prochymal), Phases I-III, 2009
Table 4.6 Clinical Trials for Graft-Versus-Host Disease, Phase II-III, 2009
Table 4.7 Countries' Donor Systems (Opt-in vs. Opt-out), 2009
Table 5.1 Osteocel Sales Forecast, 2009-2024
Table 9.1 Stem Cells Sales Forecasts, Total Market and by Sub-Market, 2009-2024
Table 10.1 Strengths and Weaknesses in the Stem Cells Market, 2009-2024
Table 10.2 Opportunities and Threats in the Stem Cells Market, 2009-2024

List of Figures
Figure 2.1 Private / Family Cord Blood Banks Sales Forecast, 2009-2024
Figure 4.1 Market Value of Selected Prochymal Future Indications, Based Upon Sales Through Q3 2008
Figure 4.2 Osteocel Sales Forecast, 2009-2024
Figure 5.1 Osteocel Sales Forecast, 2009-2024
Figure 9.1 Stem Cells Total Market Sales Forecast, 2009-2024
Figure 9.2 Stem Cells Sales Forecasts by Sub-Market, 2009-2024

Companies Listed

Advanced Cell Technology
Alliance Technology Ventures
American Spinal Injury Association (ASIA)
Anthony Nolan Trust
Assisted Human Reproductions Agency, Canada
AstraZeneca
Athersys
Australian Stem Cell Centre
Axiogenesis AG
Barts & The London NHS Trust
Bayer Schering Pharma
Biogenea-CellGenea
Blutspendedienst Baden-Württemberg - Hessen
Boston Scientific Corp.
BrainStorm Cell Therapeutics
Calibochem
California Institute for Regenerative Medicines (CIRM)
Cambridge University Hospitals
Canadian Institute of Health
Canadian Institutes of Health Research (CIHR)
CellCure Neurosciences, Ltd.
Cellerix
Cellular Dynamics
Cellular Engineering Technologies
Centre for Cellular and Molecular Biology, India
CHA Biotech Co., Ltd, Korea
Children's Hospital & Research Center, Oakland, California
Christian Medical College, Vellore, India
Clinical Research Facility for Stem Cells and Regenerative Medicine, India
Comment on Reproductive Ethics (CORE)
Cord Blood Registry, US
Cordon Vital (CBR), Mexico
Cryo-Cell International
Cytori Therapeutics
Department of Defense (US)
Deutsches Herzzentrum Muenchen
Duke University
Eli Lilly and Company
Else Kröner Fresenius Foundation
ES Cell International, Singapore
European Group for Blood and Marrow Transplantation
European Medicines Agency (EMA)
European Union Group on Ethics (EGE)
Financiadora de Estudos e Projetos (FINEP)
Food and Drug Administration (FDA)
Franziskus-Krankenhaus
Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS)
Garnet BioTherapeutics
Genzyme
German Heart Institute
Geron
Guidant Corporation
Hadassah Medical Organization
Haematology Service, University Hospital of Salamanca
Harvard Biosciences, Inc.
Harvard Stem Cell Institute
Health Resources and Services Administration
Human Fertilisation and Embryology Authority (HFEA)
Imperial College London
Institute for Medical Sciences, Nizam
Instituto de Cardiologia do Rio Grande do Sul
iPS Cells
Israeli Health Ministry
Johann Wolfgang Goethe University Hospitals
Johns Hopkins University
Johnson & Johnson Development Corporation
King's College London
Kingston University, Surrey, UK
Korea Stem Cell Bank Co., Ltd. (KSCB)
Krankenhaus der Barmherzigen Brüder Trier
Leids University Medical Centre
LifeCell India
London Development Agency
London Regenerative Medicine Network (LRMN)
M.D. Anderson Cancer Center
Medical Research Council
MediStem, Inc.
Memorial Sloan-Kettering Cancer Center
Merck KGaA
Merck Serono
Miltenyi Biotec
Ministry of Health, Brazil
Ministry of Health, Iran
Ministry of Science and Higher Education, Poland
Mytogen, Inc.
National Cancer Institute (NCI)
National Marrow Donor Program
NephrosNeuralstem, Inc.
Neuronyx
NHS Foundation Trust
Northwestern University
Northwestern University Feinberg School of Medicine, Chicago
Novartis
Novocell
NuVasive, Inc.
OSI Pharmaceuticals
Osiris Therapeutics
Parent's Guide to Cord Blood Foundation
Pfizer
Pluristem Therapeutics, Inc.
Postgraduate Institute of Medical Education and Research, India
Primogenix
ProLife Alliance
Proteus Venture Partners
Queen Mary University of London
Radius Medical, LLC
Regenetech
Reliance Life Sciences
ReNeuron
Reproductive Genetics Institute, Chicago
Roche
Royan Institute, Tehran
Safeguard Scientifics, Inc.
Schulz Foundation
SCP Vitalife Partners
Silesian School of Medicine
Singapore Stem Cell Consortium
SRH Klinikum Karlsbad-Langensteinbach
Stem Cell & Regenerative Medicine International
Stem Cell Authority, Ltd.
Stem Cell Biology and Regenerative Medicines Institute, Stanford University
Stem Cell Innovations
Stem Cell Network, Canada
Stem Cell Products Inc.
Stem Cell Research Forum of India (SCRFI)
Stem Cell Sciences
Stem Cells for Safer Medicines (SC4SM)
StemCell Technologies
Stemgent
StemLifeLine
Stemride International Limited
Stiftungsklinikum Boppard
Swiss Stem Cells Network
Texas A&M University
The Broad Foundation
The Genomics Institute of the Novartis Research Foundation
Thermo Fisher Scientific (formerly HyClone)
Transition Holdings, Inc., Ireland
UC Irvine
Universidad Autónoma de Madrid
University College London
University Hospital of Liege
University Hospital, Basel, Switzerland
University of Cambridge
University of Louisville
University of Minnesota
University of Ottawa
University of Oulu, Finland
University of Salamanca
University of Southern California
University of Texas Medical Branch, Galveston
University of Washington
US Department of Health and Human Services
ViaCell, Inc.
Washington University School of Medicine
Wilhelm Sander Foundation
World Marrow Donor Association

You have successfully subscribed. Thank you.

An internal error has occurred. Please try again later.

close